Latest News

PEFO confirms MA secured ATAGI fee delay April 18, 2019

The Pre-election Economic and Fiscal Outlook has confirmed the delay in the implementation of the new $300,000 fee for vaccine submissions to ATAGI.

'Right to Trial' in blood cancers-a limited version of Trump's 'Right to Try' April 18, 2019

Labor's $20 million commitment to a 'Right to Trial' program sounds very similar to US President Donald Trump's 'Right to Try' initiative.

MA starts communication on 'principles' Code April 18, 2019

The new Code is proposed to be substantially shorter than the current 90-page edition - potentially around 30 pages - and it will focus on 'principles' rather than detailed and explicitly worded provisions.

Pfizer goes red for World Haemophilia Day April 18, 2019

“The theme of World Haemophilia Day this year is to ‘reach out and connect with your community’ and given we are new to the CBD we thought we could make a special effort to show our support,” said Emma Bonser, Pfizer’s Rare Diseases Lead.

AusBiotech laments 'wearisome' uncertainty over fate of R&D tax incentive April 17, 2019

AusBiotech has described as "wearisome" the ongoing uncertainty over the fate of the Research and Development Tax Initiative program.

Jacinda Ardern: 'Work to be done' on PHARMAC April 17, 2019

"There are elements of our PHARMAC model that are just exemplary. However, for early access, I do think there is work to be done," said Prime Minister Jacinda Ardern.

New study reveals positive news for BI's Pradaxa April 17, 2019

The latest study of real-world data for PRADAXA (dabigatran) has delivered positive news for Boehringer Ingelheim and for patients with non-valvular atrial fibrillation.

Data on out-of-pocket costs paints a very mixed picture April 16, 2019

Around 40 per cent of the $29 billion identified as consumer out-pocket-costs was spent on a combination of non-benefit medicines and 'other' health professionals.

More intervention may be needed on gene therapies April 16, 2019

Novartis has the existing organisational capacity to support the Australian commercialisation of a gene therapy like KYMRIAH - and it was still very hard - many companies developing similar treatments have virtually no presence in Australia.

Making the case for 'US-Australia PBS Plus' April 16, 2019

What could the EU and UK ask for when it comes to PBS process? What about an update or enhancement to the provisions included in the US-Australia agreement?

Seqirus 'proud' to supply flu vaccine to NIP April 16, 2019

According to Seqirus Asia Pacific vice president of commercial operations, Dr Lorna Meldrum, “Entering a new flu season, we are reminded of the enormous impact that influenza can have on public health."

Hepatitis Australia: Need for action as the task 'just got more difficult' April 16, 2019

Hepatitis Australia has expressed understanding, disappointment and concern over MSD's decision to cease all promotion of its direct-acting antiviral for hepatitis C, ZEPATIER (grazoprevir and elbasvir).

Latest Video

Most Read

New Stories

PEFO confirms MA secured ATAGI fee delay

'Right to Trial' in blood cancers-a limited version of Trump's 'Right to Try'

MA starts communication on 'principles' Code

Pfizer goes red for World Haemophilia Day

Labor commits to 'early access' trials

AusBiotech laments 'wearisome' uncertainty over fate of R&D tax incentive

Jacinda Ardern: 'Work to be done' on PHARMAC

Sign In